Fennec Pharmaceuticals Inc.
FENC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $10 | $9 | $8 |
| % Growth | 29.1% | 10.3% | 10.4% | – |
| Cost of Goods Sold | $1 | $1 | $0 | $1 |
| Gross Profit | $12 | $9 | $8 | $7 |
| % Margin | 94.7% | 90% | 95.7% | 91.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $7 | $7 | $6 | $4 |
| SG&A Expenses | $12 | $11 | $9 | $8 |
| Sales & Mktg Exp. | $5 | $4 | $3 | $4 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $11 | $9 | $8 |
| Operating Income | -$0 | -$3 | -$1 | -$1 |
| % Margin | -1.5% | -28.3% | -9.2% | -11.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$1 | -$3 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$3 | -$1 | -$2 |
| % Margin | -5.1% | -32.7% | -13.3% | -25% |
| EPS | -0.02 | -0.12 | -0.042 | -0.072 |
| % Growth | 83.3% | -184.4% | 41.6% | – |
| EPS Diluted | -0.02 | -0.12 | -0.042 | -0.057 |
| Weighted Avg Shares Out | 28 | 28 | 28 | 27 |
| Weighted Avg Shares Out Dil | 28 | 28 | 28 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$3 | -$1 | -$1 |
| % Margin | -0% | -26.2% | -8.9% | -11.5% |